Noile-Immune Biotech

Pioneering the future of cancer immunotherapy with CAR-T cell advancements from academic innovation.

Add To Watchlist
General Information
Company Name
Noile-Immune Biotech
Founded Year
2015
Location (Offices)
Founders / Decision Makers
Yukimi Sakoda - Chief Advisor Hidenobu Ishizaki - Representative Director / Founder Koji Tamada - President & CEO, Representative, BOD
Number of Employees
-
Industries
Biotechnology
Funding Stage
Series C
Social Media

Noile-Immune Biotech - Company Profile

Noile-Immune Biotech is a pioneering cancer research organization specializing in the development of cancer immunotherapies using CAR-T cell therapy. The company, founded in 2015, has its origins in Yamaguchi University and aims to lead the future of cancer immunotherapy. Their recent ¥2.38B Series C investment on 22 March 2021 saw participation from notable investors such as Dai-ichi Life Insurance, Healthcare Innovation, Binex, BiGEN, and Shibuya Kogyo. Noile-Immune Biotech's slogan, "Pioneering the future of cancer immunotherapy with CAR-T cell advancements from academic innovation," reflects their commitment to driving advancements in the field of biotechnology.

Taxonomy: Cancer Immunotherapy, CAR-T Cell Therapy, Biotech, Cancer Research, Academic Innovation, Venture Company, Yamaguchi University, Medical Technology, Innovation, Biopharmaceuticals, Immunology, Cell Therapy, Research & Development, Oncology

Funding Rounds & Investors of Noile-Immune Biotech (4)

View All
Funding Stage Amount No. Investors Investors Date
Series C - Noile ¥2.38B 5
Dai-ichi Life Insurance, investor in Noile-Immune Biotech's Series C - Noile round Healthcare Innovation, investor in Noile-Immune Biotech's Series C - Noile round Binex, investor in Noile-Immune Biotech's Series C - Noile round BiGEN, investor in Noile-Immune Biotech's Series C - Noile round
Shibuya Kogyo 		22 Mar 2021
Corporate Round - Noile ¥1.52M 1
Yamaguchi Technology Licensing Organization, investor in Noile-Immune Biotech's Corporate Round - Noile round
31 Oct 2018
Venture Round - Noile ¥60.01M 4
Daiwa Corporate Investment, investor in Noile-Immune Biotech's Venture Round - Noile round Sosei CVC, investor in Noile-Immune Biotech's Venture Round - Noile round SAIKYO, investor in Noile-Immune Biotech's Venture Round - Noile round BiGEN, investor in Noile-Immune Biotech's Venture Round - Noile round
31 May 2018
Corporate Round - Noile ¥1.00B - 04 Sep 2017

Latest News of Noile-Immune Biotech

View All

No recent news or press coverage available for Noile-Immune Biotech.

Similar Companies to Noile-Immune Biotech

View All
Iovance Biotherapeutics, Inc. - Similar company to Noile-Immune Biotech
Iovance Biotherapeutics, Inc. Iovance is a patient-centric, collaborative organization that is driven to change the way cancer is treated.
APAC Biotech - Similar company to Noile-Immune Biotech
APAC Biotech A Biotechnology Company focused on Research and Manufacturing Of Cell Based Immunotherapy treatment for Cancer
Alliance for Cancer Gene Therapy - Similar company to Noile-Immune Biotech
Alliance for Cancer Gene Therapy Momentous change has happened, and a cancer-free future is possible -- thanks to cell and gene therapy.
CTMC - a joint venture between Resilience + MD Anderson Cancer Center - Similar company to Noile-Immune Biotech
CTMC - a joint venture between Resilience + MD Anderson Cancer Center We accelerate development + manufacturing of innovative cell therapies to cure cancer.
VaxCell Biotherapeutics Co., Ltd. - Similar company to Noile-Immune Biotech
VaxCell Biotherapeutics Co., Ltd. The Better life with Anti-cancer immunotherapy
Circle Decoration Circle Decoration

Want to dive deeper into Noile-Immune Biotech? Join now to access exclusive insights and find similar companies like this — powered by AI analytics.

Register Now